Allergic disorders
暂无分享,去创建一个
[1] P. Holt,et al. Role of microbial burden in aetiology of allergy and asthma , 1999, The Lancet.
[2] Neumann,et al. Mechanisms of deficient interferon‐γ production in atopic diseases , 1999 .
[3] D I Stuart,et al. Tick histamine-binding proteins: isolation, cloning, and three-dimensional structure. , 1999, Molecular cell.
[4] Krishnendu Roy,et al. Oral gene delivery with chitosan–DNA nanoparticles generates immunologic protection in a murine model of peanut allergy , 1999, Nature Medicine.
[5] R. Homer,et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. , 1999, The Journal of clinical investigation.
[6] Terán. Chemokines and IL‐5: major players of eosinophil recruitment in asthma , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[7] F. Patalano. Injection of anti-IgE antibodies will suppress IgE and allergic symptoms. , 1999, Allergy.
[8] J. Peat,et al. Reversing the trend: reducing the prevalence of asthma. , 1999, The Journal of allergy and clinical immunology.
[9] H. Wagner,et al. Bacterial CpG DNA activates immune cells to signal infectious danger. , 1999, Advances in immunology.
[10] D B Corry,et al. Requirement for IL-13 independently of IL-4 in experimental asthma. , 1998, Science.
[11] S. Durham,et al. Immunologic changes associated with allergen immunotherapy. , 1998, The Journal of allergy and clinical immunology.
[12] J. Bousquet,et al. Clinical efficacy of sublingual‐swallow immunotherapy: a double‐blind, olacebo‐controlled trial of a standardized five‐grass‐pollen extract in rhinitis , 1998, Allergy.
[13] E. Bröcker,et al. An antagonistic IL-4 mutant prevents type I allergy in the mouse: inhibition of the IL-4/IL-13 receptor system completely abrogates humoral immune response to allergen and development of allergic symptoms in vivo. , 1998, Journal of immunology.
[14] Epitope-specific antibody response to IgE by mimotope immunization. , 1998, Journal of immunology.
[15] G. Rook,et al. Inhibition of an established allergic response to ovalbumin in BALB/c mice by killed Mycobacterium vaccae , 1998, Immunology.
[16] C. Harding,et al. CpG Oligodeoxynucleotides Act as Adjuvants that Switch on T Helper 1 (Th1) Immunity , 1997, The Journal of experimental medicine.
[17] M. Danzig,et al. Inhibition of interleukin‐5 with a monoclonal antibody attenuates allergic inflammation , 1997, Allergy.
[18] R. Dockhorn,et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. , 1997, The Journal of allergy and clinical immunology.
[19] G. V. van Seventer,et al. Human T helper cell differentiation is regulated by the combined action of cytokines and accessory cell-dependent costimulatory signals. , 1997, Journal of immunology.
[20] C. Mackay,et al. Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody. , 1997, The Journal of clinical investigation.
[21] T. Shirakawa,et al. The Inverse Association Between Tuberculin Responses and Atopic Disorder , 1996, Science.
[22] W. Sebald,et al. Design of human interleukin-4 antagonists inhibiting interleukin-4-dependent and interleukin-13-dependent responses in T-cells and B-cells with high efficiency. , 1994, European journal of biochemistry.
[23] D. Stanworth,et al. Allergy treatment with a peptide vaccine , 1990, The Lancet.